Drug Sponsors

Precision for Medicine acquires Hobart Group Holdings

Wednesday, March 26, 2014 11:43 AM

Precision for Medicine, formed in 2012 to support next-generation approaches to drug development and commercialization, has acquired Hobart Group Holdings, a market access firm.

More... »


AstraZeneca completes purchase of Sumitomo Chemical’s stake in AstraZeneca K.K.

Wednesday, March 26, 2014 11:40 AM

AstraZeneca has completed the purchase of Sumitomo Chemical’s remaining shares in AstraZeneca K.K. The purchase was valued at approximately $102 million and gives AstraZeneca control of the entire shareholding of AstraZeneca K.K.

More... »


Report: Patients expect sponsors to help them manage their health

Friday, March 21, 2014 11:03 AM

Accenture, a global management consulting, technology services and outsourcing company, has released a survey of 2,000 patients in the U.S. taking long-term, short-term or lifestyle medications, which found that the vast majority (76%) believe pharmaceutical companies should provide services that complement the products they provide. 

More... »

NIH, three others earn AAHRPP accreditation

Thursday, March 20, 2014 02:46 PM

The nonprofit Association for the Accreditation of Human Research Protection Programs has accredited four more organizations: the U.S. National Institutes of Health; King Fahad Specialist Hospital-Dammam, Saudi Arabia; Taipei Medical University Hospital, Taiwan; and St. Jude Children’s Research Hospital, Memphis, Tenn.

More... »

StemTech to open Florida facility, hire 90

Wednesday, March 19, 2014 12:55 PM

Stemtech International, a stem cell technology company, will move its headquarters from San Clemente, Calif., to Pembroke Pines, Fla., creating 90 jobs.

More... »

Teva, NIHR form health research collaboration

Wednesday, March 19, 2014 12:50 PM

Israeli pharmaceutical company Teva will invest $20 million into U.K. clinical trials and $1 million into U.K. dementia research. Teva said it will benefit from the NIHR's translational research infrastructure and its ability to efficiently set up and deliver world-leading health research studies.

More... »

SillaJen completes Jennerex acquisition

Monday, March 17, 2014 01:44 PM

SillaJen, a privately held biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for cancer, has completed the acquisition of San Francisco-based Jennerex. Privately held Jennerex is a clinical-stage, biotherapeutics company developing best-in-class targeted oncolytic immunotherapies.

More... »

Vectura Group acquires Activaero

Monday, March 17, 2014 01:38 PM

Vectura, a product development company that focuses on the development of pharmaceutical therapies for the treatment of airways-related diseases, has acquired Activaero, a private German pharmaceutical company focused on the development of products for the treatment of respiratory diseases, for $179.6 million, to be funded through a combination of existing cash and equity.

More... »

AstraZeneca sells Alderley Park site in Cheshire, U.K.

Wednesday, March 12, 2014 01:41 PM

AstraZeneca has sold its Alderley Park site in Cheshire, U.K., to Manchester Science Parks(MSP), a Greater Manchester-based public-private partnership and science park operator.

More... »

Intrexon completes acquisition of MediStem

Monday, March 10, 2014 11:50 AM

Intrexon, a provider of synthetic biology, has completed the acquisition of San Diego-based Medistem, a pioneer in the development of Endometrial Regenerative Cells (ERCs), universal donor adult-derived stem cells with properties uniquely suited for therapeutic use with Intrexon's existing suite of synthetic biology technologies.

More... »

CenterWatch
CWWeekly

January 26

2015 CRO outlook: M&As, IPOs, strategic partnerships and increased eClinical outsourcing expected to continue

IOM, industry stakeholders propose standards, guidelines for open sharing of clinical trial data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs